Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncol 2022; 23: 1009–20—In this Article, the second sentence of the Methods section in the Summary should read “...or ipilimumab 3 mg/kg intravenously every 3 weeks for four doses.” This correction has been made to the online version as of Sept 26, 2022.
. Author manuscript; available in PMC: 2022 Oct 31.
Published in final edited form as: Lancet Oncol. 2022 Oct;23(10):e446. doi: 10.1016/S1470-2045(22)00571-X